Anxiety Disorder, Major Depressive Disorder (MDD)
Conditions
Brief summary
MAN-BIOPSY pursues the concrete research question whether novel biological and psycho-physiological clusters or categories can be defined to improve treatment and minimize side effects in psychiatry, based on a synopsis of physiological, behavioural, genetic and endocrinological parameters. One major aspect of our research approach is its focuses on the identification of dysfunctions in fundamental information processing mechanisms and neurocomputational mechanisms, and is not restricted to symptom-oriented tasks. The main objectives of MAN-BIOPSY are therefore * to identify biological and psycho-physiological parameters for major depressive disorders and anxiety disorders, and * to identify predictive markers for treatment response and type/severity of side effects for these disorders.
Interventions
DRUGEscitalopram
2-4 weeks, 5-10mg, max 20mg
Sponsors
Medical University of Vienna
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
for patients: * DSM-IV-TR diagnosis of MDD or an anxiety disorder (excluding PTSD, specific phobias, and bipolar disorder) by a structured clinical interview (SCID) * aged 18 to 50 years * drug-free within the last three months prior inclusion * willingness and competence to sign the informed consent form Inclusion Criteria for remitted subjects: * a previous DSM-IV-TR diagnosis of MDD or an anxiety disorder (excluding PTSD, specific phobias, and bipolar disorder) but no symptoms at present, determined by SCID * aged 18-50 years * drug-free within the last three months prior inclusion * willingness and competence to sign the informed consent form Inclusion Criteria for healthy control subjects: * Inclusion criteria for healthy control subjects are * willingness and competence to sign the informed consent form * aged 18-50 years * drug-free
Exclusion criteria
* concomitant major internal or neurological illness * concomitant psychiatric disorders (except depression and anxiety for patients, excluding PTSD, claustrophobia and bipolar disorder) * ingestion of any antipsychotic, antidepressant, or anti-anxiety agent within the last three months prior to the screening visit * current substance abuse * failure to comply with the study protocol or to follow the instructions of the investigating team
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SSRI induced changes in BOLD (blood oxygen level dependent) response over time | 4 vears |
| SSRI induced changes in ERPs (event-related potentials) over time | 4 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| biochemical data | 4 years | these include steroid hormone levels, vitamins, etc. |
Countries
Austria
Outcome results
None listed